Neuren Pharmaceuticals Health Care
Biotech Healthcare Pharmaceuticals

$12.25 -0.23 (-1.84%)

High $12.50	Low $12.07	Trades 2,722	Turnover $3,205,258	Volume 261,029
30 June 2023 at 4:55pm

Market Cap (11-Sep) $2,567,173,120 (454th)	Close (30-Jun) $12.25 0 (0%)	Volume (30-Jun) 261,029	Shortsold (7-Sep) 3,817,412 (3.01%) (113th)
52w High $23.76	52w Low $11.00	P/E 35.46	EPS 0.15

Short Interest

ASIC data, 7 Sep 2026

% Shorted

3.01% 0.02

vs 3.03% prior report

Most Shorted Rank

113th

of 692 shorted ASX stocks

Peak Short

6.51%

Jun 2026

Days to Cover

7.0

at 50d avg vol

View full short position history →

	Subject
	NEU NEU Ann: Change of Director's Interest Notice
	1 (current) 2 3
	NEU NEU Ann: Investor presentation, 15 June 2021
	NEU NEU Ann: Initial Director's Interest Notice
	NEU NEU Ann: Neuren CEO Jon Pilcher appointed to board of directors
	NEU NEU Ann: Neuren to present at MST Access investor conference
	NEU NEU Ann: Update - Annual General Meeting 2021
	NEU NEU Ann: Positive FDA meetings enable INDs for three Phase 2 trials
	NEU NEU Ann: Virtual AGM online guide
	NEU NEU Ann: Notice of Annual General Meeting/Proxy Form
	NEU NEU Ann: New patent issued to 2032 for Neuren's trofinetide in Canada
	NEU NEU Ann: Appendix 4G
	NEU NEU Ann: Annual Report to shareholders
	NEU NEU Ann: Quarterly report and cash flow statement for Q1 2021
	NEU NEU Ann: Investor presentation, 23 March 2021
	NEU NEU Ann: S&P DJI Announces March 2021 Quarterly Rebalance
	NEU NEU Ann: Neuren successfully completes manufacturing for Phase 2
	NEU NEU Ann: Neuren corporate presentation, 24 February 2021
	NEU NEU Ann: Neuren approaching transforming milestones in 2021
	NEU NEU Ann: Preliminary Final Report and 2020 full year accounts
	NEU NEU Ann: Change of Director's Interest Notice
	NEU NEU Ann: Notification of investor briefing webinar
	NEU NEU Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
	NEU NEU Ann: Successful Phase 1 trial for Neuren's NNZ-2591
	NEU NEU Ann: Quarterly report and cash flow statement for Q4 2020
	NEU NEU Ann: European Commission grants 3 NNZ-2591 Orphan designations
	NEU NEU Ann: Notification of investor briefing webinar
	NEU NEU Ann: Positive opinion for all 3 Orphan applications in Europe
	NEU NEU Ann: Approval received for final stage of NNZ-2591 clinical trial
	NEU NEU Ann: Quarterly report and cash flow statement for Q3 2020

Similar Companies

Cann Group

CAN

Creso Pharma

CPH

Ecofibre

EOF

Incannex Healthcare

IHL

Medical Developments International

MVP

Mayne Pharma Group

MYX

Probiotec

PBP

Recce Pharmaceuticals Ltd

RCE

Starpharma Holdings

SPL

End of Day Prices

Date	Close	Volume	Change
11-Sep	$20.25	395,494	+0.04 (0.20%)
10-Sep	$20.21	625,389	-0.30 (1.46%)
09-Sep	$20.51	229,237	-0.13 (0.63%)
08-Sep	$20.64	205,083	+0.18 (0.88%)
07-Sep	$20.46	228,623	+0.13 (0.64%)
04-Sep	$20.33	899,290	-0.24 (1.17%)
03-Sep	$20.57	297,928	+0.61 (3.06%)
02-Sep	$19.96	571,639	+0.07 (0.35%)
01-Sep	$19.89	472,075	+0.15 (0.76%)
31-Aug	$19.74	934,952	-0.71 (3.47%)
28-Aug	$20.45	597,870	-0.57 (2.71%)
27-Aug	$21.02	699,549	+0.87 (4.32%)
26-Aug	$20.15	794,759	-2.38 (10.56%)
25-Aug	$22.53	726,292	+0.08 (0.36%)
24-Aug	$22.45	362,496	-0.01 (0.04%)
8 up, 7 down, and 0 flat days

Neuren Pharmaceuticals Health Care
Biotech Healthcare Pharmaceuticals

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Neuren Pharmaceuticals Health Care Biotech Healthcare Pharmaceuticals

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Neuren Pharmaceuticals Health Care
Biotech Healthcare Pharmaceuticals